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Abstract: Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do
not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify
pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with
IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study
population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or
adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total
RNA isolated from whole blood samples of six responders and six non-responders taken before
administration of the biologic and after two weeks of therapy were analyzed using next-generation
RNA sequencing. The expression of six selected genes was measured for purposes of validation
in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-
responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold
change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were
overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21,
and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1
genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
Keywords: biomarker; gene expression; infliximab; adalimumab; ulcerative colitis; Crohn disease;
inflammatory bowel disease
1. Introduction
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn
disease (CD), is a multifactorial autoimmune disorder in which a quarter of patients are
diagnosed when aged under 18 years [1,2]. IBD, when diagnosed in children, is linked with
more extensive disease and greater complications compared to patients whose disease first
appears in adulthood [3]. Since children with pediatric IBD (pIBD) have to take current
therapy for longer, treatment must be optimized.
The use of biological therapy, such as anti-Tumor Necrosis Factor (anti-TNF) agents,
has dramatically changed the treatment of autoimmune disease, including IBD. The use
of these drugs is often linked to more severe symptoms of pIBD [4]. The only anti-TNFs
approved for pIBD are infliximab (IFX) and adalimumab (ADL). However, treatment with
biological drugs very often fails. Thus, up to 41% of children with moderate to severe CD
and treated with IFX do not achieve clinical remission [5].
Mucosal healing is the best outcome in pIBD. However, given that pIBD is a chronic
disease whose response cannot be monitored using regular biopsies, the use of non-invasive
biomarkers is highly recommended.
Trough serum anti-TNF levels and antidrug antibodies, among other serological
biomarkers, are usually measured in IBD to monitor anti-TNF treatment response [6,7].
However, neither can be measured prior to starting or during the first two weeks of anti-
TNF treatment. Trough serum anti-TNF levels as soon as six weeks after initiation of
treatment were recently reported to predict remission [8]. No earlier biomarkers have been
identified to date.
Identification of genomic biomarkers could be useful to identify groups of pIBD
patients who are less likely to respond in early stages of treatment or even before initiation.
The mRNA levels in some genes have been identified as pharmacogenomic biomarkers
of the activity of anti-TNF drugs in the inflamed tissues of adults diagnosed with IBD
or other autoimmune disorders [9–13]. However, these biomarkers are identified using
invasive techniques that are not suitable for monitoring. In addition, pharmacogenomic
biomarkers of response to anti-TNF drugs have not been extensively investigated in pIBD.
Identification of biomarkers in blood facilitates monitoring. In a recent comparison with
healthy people, several genes were differentially expressed in the blood of children, but not
adults, diagnosed with IBD during an active phase of the illness [14]. On the other hand,
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some studies in adults have revealed the usefulness of biomarkers of gene expression from
whole blood in the assessment of response to anti-TNF agents [15,16].
In the present study, we analyzed whole gene expression profiles using next-generation
sequencing of RNA in whole blood from children diagnosed with IBD. Differential gene
expression before and after two weeks of treatment with IFX or ADL was analyzed with
the aim of identifying very early biomarkers of response to IFX or ADL in pIBD.
2. Materials and Methods
2.1. Patient Samples
This study was prospective and multicentric and recruited 38 IBD patients aged
< 18 years between March 2017 and May 2019, (30 with CD and eight with UC, 17 treated
with ADL and 21 with IFX) [17]. The groups analyzed were matched for age and sex. Pa-
tients with a confirmed diagnosis of inflammatory bowel disease, aged between 1–17 years,
and who had started treatment with infliximab (5 mg/kg, 0–2–6 weeks) or adalimumab
(160/80 mg in those patients weighing more than 40 kg and 80/40 mg for those weighing
40 kg or less) were included.
Age, sex, type of IBD, anti-TNF drug, and specific disease activity scores, such as
Pediatric Crohn Disease Activity Index (PCDAI) and Pediatric Ulcerative Colitis Activity
Index (PUCAI), were collected to measure anti-TNF response, which was defined as a
decrease of at least 15 points in PCDAI or PUCAI from the start of treatment to weeks
14 (IFX) or 26 (ADL). Study data were collected and managed using Research Electronic
Data Capture (REDCap) tools hosted at Hospital General Universitario Gregorio Marañón,
Madrid, Spain [18].
2.2. Ethics Statement
This study was approved by the Ethics Committee of Hospital General Universitario
Gregorio Marañón with the number LAL-TNF-2019-01. Written, informed consent was
obtained from the patients and parents or legal guardians.
2.3. Extraction of Total RNA from Whole Blood
Blood samples were collected in Paxgene tubes (PreAnalytics, Hombrechtikon, Switzer-
land) and whole blood RNA was extracted using PAXgene Blood RNA kit (PreAnalytics)
at two different points: before the first administration of ADL or IFX (week 0) and after
two weeks of the first administration of the drug (week 2) following manufacturer’s rec-
ommendations. The total RNA concentration was measured by spectrophotometry, and
the integrity of RNA was verified by electrophoresis. Only RNA samples with an RNA
integrity number > 7 were used.
2.4. RNA Sequencing
The quality and integrity of each RNA sample were checked using both a Bioanalyzer
and a Nanodrop device before proceeding to the RNA sequencing (RNAseq) protocol. Poly
A+ RNA from 100 nanograms of total RNA was reverse transcribed and barcoded RNAseq
libraries were constructed using NEBNext Ultra II Directional RNA Library Prep Kit (New
England Biolabs) following manufacturer’s recommendations. The quality of each RNA
sample library was checked using a Bioanalyzer and a Qubit.
Libraries were sequenced at 13 pM on a HiSeq 2500 (Illumina, San Diego, CA, USA)
single-read flow cell (1 × 60) and processed with RTA v1.18.66.3. FastQ files for each
sample were obtained using bcl2fastq v2.20.0.422 software (Illumina).
Sequencing reads were aligned to the human reference transcriptome (GRCh38 v91)
and quantified with RSem v1.3.1 (Li and Dewey 2011). Raw counts were normalized
using transcripts per million and the trimmed mean of M values, transformed into log2
expression (log2[rawCount+1]), were compared to calculate fold-change and corrected
p value. Only those genes expressed with at least one count in at least 12 samples were
taken into account. As there are no gene expression changes with an associated Benjamini
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and Hochberg-adjusted p value < 0.05, we considered candidates to be confirmed as such by
qPCR genes with |log2FC| > 0.6 and a non-adjusted p value < 0.05. The RNAseq data have
been deposited with the accession number GSE159034 in the Gene Expression Omnibus
database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159034) [19].
2.5. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
Total RNA was reverse transcribed and amplified, and relative expression of GBP1,
GBP5, IGHG2, GNLY, FCGR1A, FCGR1B, ACTB, and RPL4 was quantified, as described in
Salvador-Martín [17]. ACTB and RPL4 were used for normalization and three technical
replicates were used for each sample. The oligonucleotide sequences used for gene ampli-
fication are shown in Table 1. Primer pair efficiency was used for correction and relative
expression calculated using the 2−∆∆Ct method.
Table 1. Oligonucleotide sequences used for PCR amplification.










Individual gene expression analyses at t = 0 and t = 2 weeks were performed using
ExpressionSuite v1.1 (Applied Biosystems, Foster City, CA, USA), using the responder
sample (D005) as relative quantification 1 in both times of comparison. Comparison of gene
expression changes from t = 0 to t = 2 in responder versus non-responders was performed
using GraphPad Prism (GraphPad Software, San Diego, CA, USA), using the responder
sample (D005) at t = 2 as relative quantification 1. The mean relative quantification on the
triplicated samples was used for expression and the unpaired t test applied for analyzing
responder versus non-responder groups. P values were corrected using the false discovery
rate with a confidence level of 95%. Categorical and numerical variables were compared
using the t test and the Fisher exact test, respectively. For all tests, a p value < 0.05 was
considered as statistically significant.
The statistical review was performed by a biomedical statistician.
The positive predictive value (PPV), negative predictive value (NPV), sensitivity,
specificity, and diagnostic odds ratios for relative expression of GBP1, FCGR1A, and
FCGR1B were calculated as described elsewhere [20]. The + and − likelihood ratios
were calculated with a 95% confidence interval (CI).
3. Results
3.1. Patients’ Characteristics
Thirty-eight patients (29 responders and nine non-responders) met the inclusion
criteria and were included in the study. The failure rate was 23.7%. The characteristics of
both groups of patients are summarized in Table 2.
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Table 2. Characteristics of patients.
Characteristic Overall (n = 38) Responders (n = 29) Non-Responders (n = 9) p Value
Gender
Male, n (%) 20 (52.6%) 15 (51.7%) 5 (55.6%) 1
Female, n (%) 18 (47.4%) 14 (48.3%) 4 (44.4%)
Age (years)
At diagnosis, median (IQR,
range) 10.5 (4.55, 0.7–17) 10.5 (4.63, 2–17) 10.2 (7.5, 0.7–13) 0.137
At start of treatment, median
(IQR, range) 11.9 (4.15, 1.1–17) 12.2 (4.6, 3.5–17) 11.5 (6, 1.1–14.1) 0.263
Type of IBD
CD, n (%) 30 (78.9%) 22 (75.9%) 8 (88.9%) 0.650
UC, n (%) 8 (21.1%) 7 (24.1%) 1 (11.1%)
Type of Anti-TNF
Infliximab, n (%) 21 (55.3%) 14 (48.3%) 7 (77.8%) 0.148
Adalimumab, n (%) 17 (44.7%) 15 (51.7%) 2 (22.2%)
PCDAI at start of treatment,
median (IQR, range) 28.75 (25.63, 5–60) 32.5 (31.25, 5–60) 16.25 (11.25, 7.5–30) 0.045 **
PUCAI at start of treatment,
median (IQR, range) 47.5 (35, 5–60) * 50 (40, 5–60) 45 * -
CRP at start of treatment,
median (IQR, range) 14.09 (28.54, 0.4–110.9) 22.3 (32.19, 0.4–110.9) 8.45 (17.94, 4–27.5) 0.042 **
FC at start of treatment,
median (IQR,
range)Concomitant
immunomodulator at start of
treatment
1800 (2253, 27–9543) 2000 (2288, 27–9543) 1207.5 (1432, 130–3167) 0.106
Azathioprine, n (%) 26 (68.4%) 22 (75.9%) 4 (44.4%)
Methotrexate, n (%) 4 (10.5%) 4 (13.8%) 0 0.006 **
None, n (%) 8 (21.1%) 3 (10.3%) 5 (55.56%)
IBD, inflammatory bowel disease; CD, Crohn disease; UC, ulcerative colitis; IQR, interquartile range; PCDAI, Pediatric Crohn Disease
Activity Index; PUCAI, Pediatric Ulcerative Colitis Activity Index; CRP, C-reactive protein; FC, fecal calprotectin. * IQR not applicable.
** p value < 0.05.
Patients were mainly male (52.6%; median age at diagnosis, 10.5 years), diagnosed
with CD (78.9%), and treated with IFX (55.3%). The statistical differences between both
groups were in the PCDAI and C-reactive protein (CRP) levels at initiation of treatment
(16.25 in non-responders versus 32.5 in responders [p = 0.045] and 8.45 in non-responders
versus 22.3 in responders [p = 0.042]) and in the concomitant immunomodulator at initiation
of treatment.
The demographic and clinical variables of the six responders and six non-responders
selected for RNAseq were more homogeneous than those of the total population (Supple-
mentary Materials Table S1). In these patients only PCDAI was statistically significant
between both groups (p = 0.025).
3.2. Differential Gene Expression Using RNAseq in the Response of Anti-TNF Agents Prior to
Starting Treatment
Twenty genes were overexpressed and two downregulated in non-responders versus
responders (Log2FC [Fold change] > 0.6 or <–0.6 and p value < 0.05) immediately prior
to the first administration of the anti-TNF agent (Table 3). For this analysis, the relative
expression of the whole transcriptome using RNAseq was measured in six responders and
six non-responders. Responders were used as the reference group.
Pharmaceutics 2021, 13, 77 6 of 17
Table 3. List of genes expressed differentially between responders (R) and non-responders (NR) prior to initiation of
anti-TNF treatment.




TMM+1 NR Log2 NR
Fold Change
(Log2) p Value
HK2 46.41 5.98 2.56 26.02 3.69 1.89 −0.67 0.0254
DNAJC13 32.18 4.19 2.07 16.19 2.67 1.42 −0.65 0.0107
TSPAN33 13.53 2.47 1.31 25.58 3.77 1.91 0.61 0.0096
MAP3K7CL 15.98 2.73 1.45 30.07 4.16 2.06 0.61 0.0110
TRBC2 171.80 17.93 4.16 245.97 27.67 4.79 0.63 0.0180
MT-CO3 1097.32 120.77 6.92 1767.21 187.72 7.55 0.64 0.0136
CCL4 6.51 1.61 0.69 14.43 2.53 1.34 0.65 0.0276
DDX11L10 3.54 1.39 0.47 12.37 2.18 1.13 0.65 0.0495
MT-ND4L 132.36 15.82 3.98 227.85 25.23 4.66 0.67 0.0392
MT-ATP6 1024.97 115.51 6.85 1739.84 186.20 7.54 0.69 0.0253
MT-CYB 868.49 99.71 6.64 1494.58 162.26 7.34 0.70 0.0382
ACRBP 11.09 2.30 1.20 25.66 3.76 1.91 0.71 0.0020
TREML1 13.74 2.71 1.44 31.99 4.50 2.17 0.73 0.0297
MT-ND1 1094.43 126.98 6.99 1989.71 212.16 7.73 0.74 0.0423
HLA-C 1809.25 194.04 7.60 2990.89 325.05 8.34 0.74 0.0080
HLA-H 80.05 9.74 3.28 140.43 16.50 4.04 0.76 0.0361
AP001189.1 10.66 2.32 1.21 26.74 3.92 1.97 0.76 0.0221
MT-ATP8 107.65 13.26 3.73 202.76 22.62 4.50 0.77 0.0251
MT-ND2 865.51 99.05 6.63 1596.88 169.80 7.41 0.78 0.0168
SH3BGRL2 8.73 2.04 1.03 24.59 3.54 1.82 0.80 0.0294
IFITM3 327.49 37.05 5.21 594.78 65.05 6.02 0.81 0.0181
KLRD1 37.29 4.30 2.11 61.96 7.61 2.93 0.82 0.0491
TUBB1 76.43 10.11 3.34 163.15 17.92 4.16 0.83 0.0259
GP1BB 22.65 3.79 1.92 53.23 6.71 2.75 0.83 0.0172
IFITM1 373.17 43.37 5.44 727.55 77.03 6.27 0.83 0.0459
OASL 23.87 3.31 1.73 50.93 5.98 2.58 0.85 0.0423
PF4 23.49 3.63 1.86 60.29 7.32 2.87 1.01 0.0049
EPSTI1 41.88 4.57 2.19 83.41 9.27 3.21 1.02 0.0344
MYL9 11.02 2.41 1.27 38.53 5.20 2.38 1.11 0.0269
CCL5 122.76 13.85 3.79 276.24 30.37 4.92 1.13 0.0002
MYOM2 2.67 1.23 0.30 15.28 2.86 1.52 1.22 0.0377
GNLY 62.70 6.77 2.76 191.26 21.55 4.43 1.67 0.0409
TPM, transcripts per million; TMM, trimmed mean of M values; R, responder; NR, non-responder.
The most overexpressed gene in non-responders was GNLY (2.8 fold). The most
downregulated gene in the same patients was DNAJC13 (2.4 fold).
3.3. Differential Gene Expression in Response to Anti-TNF Agents at Week 2 Post-Treatment
Twenty-six genes were overexpressed in non-responders and 16 were downregulated
in responders (Log2FC [Fold change] >0.6 or <−0.6 and p value < 0.05) at two weeks
post-treatment with anti-TNFs (Table 4). Responders were used as the reference group.
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Table 4. List of genes expressed differentially between responders (R) and non-responders (NR) after two weeks of anti-TNF
treatment.




TMM+1 NR Log2 NR
Fold Change
(Log2) p Value
IGHG1 492.65 54.71 5.77 98.10 11.26 3.49 −2.28 0.0394
IGKV3-20 92.59 11.12 3.47 37.71 4.50 2.17 −1.30 0.0096
IGHG2 163.72 19.68 4.30 71.31 8.06 3.01 −1.29 0.0372
IGHA1 510.70 57.75 5.85 254.62 25.75 4.69 −1.17 0.0268
IGKC 1398.17 155.23 7.28 669.09 70.45 6.14 −1.14 0.0159
IGKV1-39 45.72 5.83 2.54 18.16 2.83 1.50 −1.04 0.0313
IGKV2D-28 35.88 5.17 2.37 15.11 2.54 1.34 −1.03 0.0061
IGHV4-59 14.97 2.63 1.40 5.01 1.45 0.54 −0.86 0.0272
IGKV1-5 42.43 5.66 2.50 21.94 3.14 1.65 −0.85 0.0380
IGHV3-74 12.98 2.48 1.31 4.11 1.40 0.49 −0.82 0.0091
IGKV3-11 32.50 4.50 2.17 15.11 2.56 1.36 −0.81 0.0070
IGKV3-15 39.70 5.50 2.46 21.91 3.14 1.65 −0.81 0.0300
IGKV1-12 15.46 2.63 1.40 6.00 1.59 0.67 −0.72 0.0095
IGHV3-7 16.04 2.85 1.51 7.78 1.74 0.80 −0.72 0.0146
IGHV3-48 8.96 1.95 0.97 2.03 1.20 0.26 −0.70 0.0459
IGLV1-44 28.69 4.13 2.05 15.36 2.54 1.35 −0.70 0.0272
RARRES3 27.27 4.05 2.02 46.58 6.15 2.62 0.60 0.0327
RHBDF2 46.64 6.02 2.59 75.71 9.17 3.20 0.61 0.0281
IGFLR1 22.43 3.47 1.80 40.98 5.39 2.43 0.63 0.0070
APOL2 67.33 8.64 3.11 117.78 13.65 3.77 0.66 0.0385
TYMP 266.66 30.75 4.94 451.43 48.71 5.61 0.66 0.0444
IL1B 29.29 4.23 2.08 53.16 6.72 2.75 0.67 0.0226
DNAJC25-
GNG10 26.40 3.93 1.98 51.09 6.29 2.65 0.68 0.0397
GZMA 14.86 2.62 1.39 29.03 4.20 2.07 0.68 0.0493
IRF1 307.23 35.90 5.17 538.82 58.4 5.87 0.70 0.0295
HLA-C 1710.59 197.19 7.62 2939.53 323.41 8.34 0.71 0.0096
HLA-H 77.17 9.96 3.32 139.23 16.44 4.04 0.72 0.0378
APOL6 93.85 11.01 3.46 166.82 18.54 4.21 0.75 0.0205
DHRS9 17.27 2.75 1.46 35.50 4.73 2.24 0.78 0.0197
UBE2L6 91.58 11.15 3.48 168.82 19.24 4.27 0.79 0.0272
ODF3B 26.61 3.85 1.95 56.06 6.92 2.79 0.84 0.0273
GBP2 200.76 23.37 4.55 393.53 42.06 5.39 0.85 0.0118
SECTM1 128.31 15.52 3.96 252.39 28.29 4.82 0.87 0.0484
FCGR1CP 4.89 1.47 0.56 18.76 3.13 1.65 1.09 0.0313
SERPING1 20.09 3.07 1.62 56.06 6.79 2.76 1.14 0.0293
MYOM2 2.43 1.27 0.34 14.53 2.80 1.48 1.14 0.0389
GBP1 84.92 9.85 3.30 208.64 22.49 4.49 1.19 0.0201
ANKRD22 3.24 1.34 0.42 19.72 3.11 1.64 1.22 0.0382
FCGR1B 33.63 4.77 2.25 106.67 12.48 3.64 1.39 0.0293
FCGR1A 27.68 4.15 2.05 93.02 10.90 3.45 1.39 0.0212
BATF2 6.67 1.69 0.76 36.71 4.89 2.29 1.53 0.0201
GBP5 130.99 14.13 3.82 393.84 41.43 5.37 1.55 0.0373
TPM, transcripts per million; TMM, trimmed mean of M values; R, responder; NR, non-responder.
The most overexpressed gene in non-responders was GBP5 (2.4 fold). The most
downregulated gene in the same patients was IGLV1-44 (2.4 fold).
3.4. Functional in Silico Analysis
Functional analysis of differentially expressed genes was performed using Ingenuity
Pathways Analysis (IPA, Qiagen, Germany).
Developmental disorder (p value range 1.96 × 10−2 to 9.23 × 10−15), cell-to-cell
signaling interaction (p value range 1.96 × 10−2 to 4.30 × 10−9), and hematological system
development and function (p value range 1.96 × 10−2 to 4.30 × 10−9) were found to be the
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most significant disease and biofunctions represented by all of the selected genes prior to
initiation of treatment (Supplementary Materials Table S2).
Figure 1 shows the main network generated by IPA and based on known interactions
between the genes expressed differentially between responders and non-responders prior
to initiation of anti-TNF treatment. The main diseases and functions associated with this
network were developmental disorder, hereditary disorder, and metabolic disease.
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Figure 1. Network of differentially expressed genes prior to initiation of anti-TNF therapy based on interactions using
Ingenuity Pathway Analysis. Red, genes overexpressed in non-responders vs. responders; green, genes downregulated in
non-responders vs. responders.
The results for all of the genes selected after two weeks of anti-TNF treatment showed
inflammatory response (p value range 1.30 × 10−2 to 5.74 × 10−23), cellular function and
maintenance (p value range 1.19 × 10−2 to 5.11 × 10−19), and humoral immune response
(p value range 1.23 × 10−2 to 5.74 × 10−23) to be the most significant disease and bio-
functions represented by the selected genes after two weeks of treatment (Supplementary
Materials Table S3)
The most informative network generated by IPA and based on known interactions
between the genes differentially expressed between responders and non-responders after
two w eks of anti-TNF treatment is represented in Figure 2. The top disease and functions
a sociated with this network were consistent with those obtained for all of the selected
genes, namely, f ti and maintenance, humoral im une response, and inflam-
matory response. For this reason, we decided to select ost s for validation
from among the genes that were di ferentia ly expre sed after two weeks of treat ent.
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3.5. Validation of Differentially Expressed Genes by qRT-PCR
Eight genes were selected from the RNAseq analyses for validation by real-time PCR
(one differentially expressed at T0 and seven at T2). Semiquantitative real-time PCR was
performed to assess RNA from patients’ blood prior to treatment and after two weeks
of treatment (Figure 3). None of the genes studied was expressed differentially between
responders and non-responders before initiation of anti-TNF treatment.
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Figure 3. Relative expression levels of the genes GBP1 (a,b), GBP5 (c,d), GNLY (e,f), BATF2 (g,h), 
IGHA1 (i,j), IGHG2 (k,l), FCGR1A (m,n), and FCGR1B (o,p) in responders (R, green) and non-re-
sponders (NR, orange) at time 0 (t = 0) and at two weeks (t = 2) after initiation of anti-TNF therapy. 
Expression values were normalized to the ACTB and RPL4 genes. Values are expressed as mean 
(horizontal line) and standard error of the mean (SEM); n, sample size; * p value < 0.05 vs. control 
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Figure 3. Relative expression levels of the genes GBP1 (a,b), GBP5 (c,d), GNLY (e,f), BATF2 (g,h),
IGHA1 (i,j), IGHG2 (k,l), FCGR1A (m,n), and FCGR1B (o,p) in responders (R, green) and non-
responders (NR, orange) at time 0 (t = 0) and at two weeks (t = 2) after initiation of anti-TNF therapy.
Expression values were normalized to the ACTB and RPL4 genes. Values are expressed as mean
(horizontal line) and standard error of the mean (SEM); n, sample size; * p value < 0.05 vs. control
(unpaired t test).
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GBP1 was overexpressed in non-responders compared with responders after two
weeks of treatment (LogFC = 1.08, p value 0.006, False Discovery Rate (FDR) 0.032). In
addition, FCGR1A and FCGR1B were also induced 1.05 fold more in non-responders
(p value = 0.006, FDR 0.035) and 1.21 fold more in responders (p value = 0.005; FDR 0.032)
(in LogFC). No other statistically significant changes were detected.
A comparison of the results for changes in gene expression using RNAseq and qRT-
PCR (Table 5) revealed a good correlation, mainly in the data on genes selected after two
weeks of anti-TNF treatment (R2 = 0.83). The differences were statistically significant using
both techniques in three cases.
Table 5. Correlation between RNAseq and qRT-PCR for selected genes.







GBP1 0.69 0.49 1.19 * 1.08 *
GBP5 0.95 0.19 1.55 * 0.78
GNLY 1.67 * 0.54 1.35 1.15
BATF2 1.16 0.48 1.53 * 0.55
IGHA1 −0.76 −0.67 −1.17 * −0.34
IGHG2 −0.29 −0.01 −1.29 * −0.23
FCGR1A 0.22 0.39 1.39 * 1.05 *
FCGR1B 0.25 0.66 1.39 * 1.21 *
* p value < 0.05.
3.6. Prediction of Response to Anti-TNF Therapy Based on Expression of GBP1, FCGR1A, and
FCGR1B after Two Weeks of Treatment
Expression of GBP1, FCGR1A, and FCGR1B mRNA at T2 was higher in non-responders
than in responders (Figure 4). The PPV, NPV, sensitivity, specificity, diagnostic odds ratio,
positive likelihood ratio (+LR), and negative likelihood ratio (–LR) are presented in Table 6.
The best diagnostic odds ratio corresponds to FCGR1B expression
3.7. Differences in Gene Expression between Responders and Non-Responders during the First Two
Weeks of Anti-TNF Therapy
Changes in gene expression from T0 to T2 were measured for the eight selected genes
when responders and non-responders were compared (Figure 4). Only FCGR1A changed
its expression during the first two weeks of treatment (p value < 0.05). An increase in
FCGR1A expression was observed in non-responders, while a decrease was observed in
responders. Similar trends were observed for GBP1 and FCGR1B, although the differences
were not statistically significant.
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Figure 4. Schematic representation of the ratio between relative expression levels at week 2 (T2)
and week 0 (T0) (T2/T0) of the genes GBP1 (a), GBP5 (b), GNLY (c), BATF2 (d), IGHA1 (e), IGHG2
(f), FCGR1A (g), and FCGR1B (h) in responders (R) and non-responders (NR). Expression values
were normalized to the ACTB and RPL4 genes. Values are expressed as mean (horizontal line) and
standard error of the mean (SEM); n, sample size; * p value < 0.05 vs. control (unpaired t test).
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Table 6. Diagnostic values of GBP1, FCGR1A, and FCGR1B expression after two weeks of anti-TNF
treatment.
GBP1 1 FCGR1A 1 FCGR1B 1
Sensitivity 67% 78% 89%
Specificity 70% 63%1 52%
PPV 43% 41% 38%
NPV 86% 89% 93%
Diagnostic odds ratio 4.75 5.95 8.61
+LR 2,25 2.1 1.84
–LR 0.47 0.35 0.21
1 Relative expression cut-off: GBP1 = 0.3, FCGR1A = 0.5, and FCGR1B = 0.39.
4. Discussion
The use of biologic drugs such as anti-TNF agents has dramatically transformed the
treatment of autoimmune diseases, including IBD. However, more than 20% of patients do
not respond correctly to this therapy [6]. The identification of the patients in whom therapy
is more likely to fail in early stages or even before initiation would enable therapy to be
personalized. The benefits of personalization in terms of safety and efficacy are of particular
interest in children, who are necessarily treated for longer. Finding specific biomarkers for
children is necessary since genetics has a more important role in pIBD than in adult disease.
Consequently, several gene polymorphisms have been involved in susceptibility to pIBD or
to very-early-onset ulcerative colitis [21,22]. The serum levels of proteins, such as clusterin
and ceruloplasmin, also differ between children and adults with IBD [23]. As for response,
genetic polymorphisms in genes such as ATG16L1, CDKAL1, ICOSLG, BRWD1, and HLA-
DQA1 have been associated with the response to anti-TNF treatment in children [24]. In
contrast, several genes associated with expression and response to anti-TNF response have
been identified only in adults with IBD [9,10,13]. Our group recently showed expression
of SMAD7 in blood to be a biomarker of the response to anti-TNF agents two weeks after
initiation of treatment [17]. To our knowledge, ours is the first study to assess whole gene
expression profile by RNAseq in pIBD using biomarkers of response to anti-TNF agents.
We identified putative gene networks and pathways involved in early response in pIBD and
validated GBP1, FCGR1A, and FCGR1B as potential pharmacogenomic markers. Although
we are still at a very early stage, the identification of these non-invasive biomarkers in
pediatric IBD could revolutionize the selection of biological drug treatment in these patients
in the future.
Humoral immune response, inflammatory response, and maintenance of cellular
function were associated with the differentially expressed genes in responders and non-
responders after two weeks of anti-TNF treatment. These diseases and biofunctions are
clearly associated with IBD and indicate that our strategy could be helpful for identifying
biomarkers of response to anti-TNF agents [25,26]. However, since these diseases and
biofunctions are too extensive and provide little information in terms of prediction, we
decided to focus on the differentially expressed genes verified by qPCR.
Certainly, only three out of eight genes were statistically validated. However, the
correlation between log2 ratios (RNAseq) and relative quantification (RT-qPCR) was as high
as R2 = 0.83. This value was lower than those found in other works with ideal conditions
for comparison [27]. Nevertheless, it was similar or even higher than the values found in
other works with more variable samples, such as tissues from living organisms [28,29].
We found that expression of GBP1 mRNA was upregulated in the peripheral blood
cells of non-responders after two weeks of anti-TNF treatment. GBP1 is an interferon-
stimulated, guanylate-binding protein involved in defense against pathogens and inflam-
mation; its levels are elevated in the mucosa of patients with active disease [30]. The fact
that this gene was overexpressed in non-responders after two weeks of treatment suggests
a higher likelihood of inflammation and a higher risk of treatment failure.
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Similarly, GBP1 was identified as differentially expressed in colitis-susceptible mice
and in colitis-resistant mice [31].
Our results also revealed greater expression of the FCGR1A and FCGR1B genes in
non-responders after two weeks of anti-TNF treatment. FCRG1A, also known as CD64, is
upregulated in adults and children diagnosed with clinically active IBD [32] and has been
related to calprotectin level [33]. FCRG1A and FCGR1B are expressed on the surface of
neutrophils and have been suggested to be potential therapeutic targets [34]. Furthermore,
both ADL and IFX are less effective in the peripheral blood mononuclear cells of adult
IBD patients who express elevated levels of CD64 [35]. Here, we demonstrated a similar
usefulness of these genes as biomarkers of response to anti-TNF drugs in children with IBD.
There are several limitations of this study. First, the sample size is small for a study of
these characteristics [12,16]. Second, our results do not distinguish between the two drugs
administered to patients, infliximab and adalimumab. Thus, although the mechanism of
action of both drugs is similar, we cannot rule out a differential effect. Third, it is necessary
to define the role of the PCDAI index in the causality of the response to anti-TNFs. Finally,
the comparison with other works is complicated by differences in the study population, as
well as in the evaluation criteria of the response [9,13].
Future research will require more studies involving larger populations to confirm our
findings. Single-cell RNAseq might be useful to rule out the effect of mixed-cell populations.
In addition, a larger sample size could help to differentiate biomarkers by anti-TNF drug
and by type of pIBD. In spite of these limitations, the identification of GBP1, FCGR1A, and
FCGR1B as blood biomarkers of response to anti-TNF agents shows great potential for the
personalization of therapy in pIBD.
5. Conclusions
We identified the expression levels of GBP1, FCGR1A1, and FCGR1B1 genes as poten-
tial biomarkers of response to treatment with IFX and ADL in children with IBD.
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